tadalafil has been researched along with Acute Confusional Senile Dementia in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 6 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Arancio, O; Deng, SX; Feng, Y; Fiorito, J; Francis, YI; Landry, DW; Rao, S; Saeed, F; Staniszewski, A; Thakkar, DM; Zhang, H | 1 |
| Cuadrado-Tejedor, M; de Miguel, I; Espelosin, M; Estella-Hermoso de Mendoza, A; García-Barroso, C; Garcia-Osta, A; Haizhong, T; Musheng, X; Oyarzabal, J; Pérez-González, M; Rabal, O; Sáez, E; Sánchez-Arias, JA; Ugarte, A; Ursua, S; Wei, W | 2 |
| Huang, YY; Li, Z; Luo, HB; Wu, D; Wu, Y | 1 |
| Xu, J; Xu, S; Zhang, P; Zhu, Z | 1 |
| Dong, YH; Huang, XF; Ke, HM; Song, GQ; Wang, JH; Xu, DF | 1 |
| Chai, S; Chen, S; Deng, L; Du, K; Shen, R; Sun, H; Sun, T; Xi, M; Xie, M | 1 |
| Henry, DS; Pellegrino, RG | 1 |
| Ding, S; Huang, X; Liu, L; Song, G; Wang, D; Xu, H | 1 |
| Akhtar, M; Hasan, N; Najmi, AK; Parvez, S; Yar, MS; Zameer, S | 1 |
| Budzyńska, B; El Sayed, NS; Kowalczyk, J; Mansour, SM; Salem, MA | 1 |
| Hopkins Tanne, J | 1 |
| Cuadrado-Tejedor, M; Franco, R; García-Barroso, C; García-Osta, A; Goicolea, MA; Lanciego, JL; Oyarzabal, J; Pascual-Lucas, M; Rico, AJ; Ricobaraza, A; Sallés, J; Unceta, N | 1 |
4 review(s) available for tadalafil and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Cognition; Humans; Phosphodiesterase Inhibitors | 2018 |
Multi-target design strategies for the improved treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Chelating Agents; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Neuroprotective Agents; Nootropic Agents; Receptors, Cell Surface; Signal Transduction | 2019 |
Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Alzheimer Disease; Animals; Cognition; Cyclic GMP; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases | 2022 |
Phosphodiesterase 5 inhibitors as novel agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cognition; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 5; Flavonoids; Humans; Neurons; Neuroprotective Agents; Phosphodiesterase 5 Inhibitors; Purinones; Pyrimidines; Signal Transduction; Sildenafil Citrate; Sulfonamides; Tadalafil; Vardenafil Dihydrochloride | 2019 |
10 other study(ies) available for tadalafil and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Drug Discovery; Female; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Phosphodiesterase 5 Inhibitors; Quinolines | 2013 |
Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.
Topics: Acetylation; Alzheimer Disease; Animals; Cell Line; Cells, Cultured; Cyclic AMP Response Element-Binding Protein; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Design; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Mice; Models, Molecular; Phosphodiesterase 5 Inhibitors | 2016 |
Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cell Line; Cyclic Nucleotide Phosphodiesterases, Type 5; Dose-Response Relationship, Drug; Drug Design; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Molecular Structure; Neuroglia; Phosphodiesterase 5 Inhibitors; Structure-Activity Relationship | 2018 |
Novel PDE5 inhibitors derived from rutaecarpine for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cholinergic Antagonists; Cognitive Dysfunction; Cyclic Nucleotide Phosphodiesterases, Type 5; Dose-Response Relationship, Drug; Indole Alkaloids; Mice; Models, Molecular; Molecular Structure; Morris Water Maze Test; Phosphodiesterase 5 Inhibitors; Protein Conformation; Quinazolines; Scopolamine | 2020 |
Phosphodiesterase-5 inhibitors for Alzheimer's disease?
Topics: Alzheimer Disease; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Humans; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Sulfones; Tadalafil | 2022 |
A case-control study of phosphodiesterase-5 inhibitor use and Alzheimer's disease and related dementias among male and female patients aged 65 years and older supporting the need for a phase III clinical trial.
Topics: Aged; Alzheimer Disease; Case-Control Studies; Cyclic Nucleotide Phosphodiesterases, Type 5; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil | 2023 |
Roflumilast and tadalafil improve learning and memory deficits in intracerebroventricular Aβ1-42 rat model of Alzheimer's disease through modulations of hippocampal cAMP/cGMP/BDNF signaling pathway.
Topics: Alzheimer Disease; Aminopyridines; Amyloid beta-Peptides; Animals; Benzamides; Brain-Derived Neurotrophic Factor; Cyclic AMP; Cyclic GMP; Cyclopropanes; Cytokines; Gene Expression Regulation; Hippocampus; Male; Memory Disorders; Morris Water Maze Test; Oxidative Stress; Peptide Fragments; Random Allocation; Rats; Rats, Wistar; Tadalafil; Vasodilator Agents | 2021 |
Tadalafil and bergapten mitigate streptozotocin-induced sporadic Alzheimer's disease in mice via modulating neuroinflammation, PI3K/Akt, Wnt/β-catenin, AMPK/mTOR signaling pathways.
Topics: 5-Methoxypsoralen; Alzheimer Disease; AMP-Activated Protein Kinases; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents; Behavior, Animal; Cognition; Disease Models, Animal; Hippocampus; Male; Mice; Morris Water Maze Test; Neuroinflammatory Diseases; Open Field Test; Phosphatidylinositol 3-Kinase; Phosphorylation; Proto-Oncogene Proteins c-akt; Streptozocin; Tadalafil; tau Proteins; TOR Serine-Threonine Kinases; Wnt Signaling Pathway | 2021 |
Approved drugs are to be studied for use in Alzheimer's disease.
Topics: Alzheimer Disease; Drug Approval; Drug Repositioning; Humans; Levetiracetam; Nootropic Agents; Piracetam; Tadalafil; Vasodilator Agents | 2016 |
Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD.
Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Brain; Carbolines; Cognition Disorders; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Female; Gene Expression Regulation, Enzymologic; Half-Life; Humans; Macaca fascicularis; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nootropic Agents; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Species Specificity; Sulfones; Tadalafil; Tissue Distribution | 2013 |